Liu Qingxin, Jernigan Danielle, Zhang Yun, Fatatis Alessandro
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Chin J Cancer. 2011 Sep;30(9):612-9. doi: 10.5732/cjc.011.10225.
Metastasis represents by far the most feared complication of prostate carcinoma and is the main cause of death for patients. The skeleton is frequently targeted by disseminated cancer cells and represents the sole site of spread in more than 80% of prostate cancer cases. Compatibility between select malignant phenotypes and the microenvironment of colonized tissues is broadly recognized as the culprit for the organ-tropism of cancer cells. Here, we review our recent studies showing that the expression of platelet-derived growth factor receptor alpha (PDGFRα) supports the survival and growth of prostate cancer cells in the skeleton and that the soluble fraction of bone marrow activates PDGFRα in a ligand-independent fashion. Finally, we offer pre-clinical evidence that this receptor is a viable target for therapy.
转移是前列腺癌目前最可怕的并发症,也是患者死亡的主要原因。骨骼经常成为播散癌细胞的靶器官,在超过80%的前列腺癌病例中,骨骼是唯一的转移部位。特定恶性表型与定植组织微环境之间的兼容性被广泛认为是癌细胞器官嗜性的罪魁祸首。在此,我们回顾了我们最近的研究,这些研究表明血小板衍生生长因子受体α(PDGFRα)的表达支持前列腺癌细胞在骨骼中的存活和生长,并且骨髓的可溶性部分以不依赖配体的方式激活PDGFRα。最后,我们提供临床前证据表明该受体是一个可行的治疗靶点。